

JNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	
07713776	SINGH	L	5454-41-EMA	
WARNER LAMBERT COMPANY 2800 PLYMOUTH ROAD ANN ARBOR MI 48105	NM12/0129 —		EXAMINER	
	·	REAM	ER, J	
		ART UNIT	PAPER NUMBER	
		1614	e	
		DATE MAILE	o: 01/29/99	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. 09/043,358

Applicant(s)

Shingh

Office Action Summary

Examiner

James H. Reamer

Group Art Unit 1614



Responsive to communication(s) filed on	·
This action is FINAL.	
Since this application is in condition for allowance except for in accordance with the practice under <i>Ex parte Quayle</i> , 1939	
A shortened statutory period for response to this action is set to solve, from the mailing date of this communication. Failure pplication to become abandoned. (35 U.S.C. § 133). Extension CFR 1.136(a).	to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
X Claim(s) 1-15	is/are rejected.
Claim(s)	is/are objected to.
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	g Review, PTO-948.
☐ The drawing(s) filed on is/are object	ted to by the Examiner.
☐ The proposed drawing correction, filed on	is 🗖 approved 🗖 disapproved.
☐ The specification is objected to by the Examiner.	
The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	•
🛛 Acknowledgement is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d).
	of the priority documents have been
☐ received.	
received in Application No. (Series Code/Serial Nur	
□ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the □ received in this national stage application from the received in the	International Bureau (PCT Rule 17.2(a)).
*Certified copies not received: Acknowledgement is made of a claim for domestic priority	tu under 25 II C. 6 110/o\
Acknowledgement is made of a claim for domestic priori	ty under 35 0.3.C. 3 113(e).
Attachment(s)	
☒ Notice of References Cited, PTO-892☒ Information Disclosure Statement(s), PTO-1449, Paper N	(a(s) 5
☐ Interview Summary, PTO-413	0,07.
	48
☐ Notice of Draftsperson's Patent Drawing Review, PTO-94	

6

Application/Control Number: 09/043,358

Page

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1 to 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Field et al or Mellick et al. Each of the references teach the use of the instant compounds for the management of pain in humans. The determination of the various types of pains which would be able to be managed by the instant compounds is considered to be easily determinable by one skilled in the art given the teaching of the two references. The instant claims are considered to be prim facie obvious over the cited references absent evidence of unexpected results.

Conclusion .

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The references are cited to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James H. Reamer whose telephone number is (703) 308-4461.

JHR

January 25, 1999

JAMES H. REAMER

PRIMARY EXAMINER
GROUP 160°- ART UNIT 1614